This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
No Author listed. 1Q Stock Wrap-Up. BioCentury 14, No.15, 9–11 (2006).
No Author listed. 2Q Stock Wrap-Up. BioCentury 14, No. 29, 10–13 (2006).
No Author listed. 3Q Stock Wrap Up. BioCentury 14, No. 43, 10–13 (2006).
Edelson, S. 4Q Stock Wrap-Up. BioCentury 15, No. 1, 8–12 (2007).
No Author listed. 1Q Stock Wrap-Up. BioCentury 15, No. 15, 9–12 (2007).
Lawrence S. 2Q Stock Wrap-Up. BioCentury 15, No. 29, 10–13 (2007).
Lawrence, S. 3Q Stock-Wrap-Up. BioCentury 15 No. 43, 9–12 (2007).
Lawrence, S. 4Q Stock Wrap-Up. BioCentury 16 No. 2, 20–25 (2008).
Sabo, S. The current status of targeted therapies for breast cancer: an interview with Kathy Miller, MD. Medscape web site [online], (2003).
Keymeulen, B. et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352, 2598–2608 (2005).
Drews, J. & Ryser, S, Innovation deficit in the pharmaceutical industry. Drug Inf. J. 30, 97–107 (1996).
About this article
Cite this article
Czerepak, E., Ryser, S. Drug approvals and failures: implications for alliances. Nat Rev Drug Discov 7, 197–198 (2008). https://doi.org/10.1038/nrd2531
This article is cited by
Cancer Chemotherapy and Pharmacology (2014)
Nature Biotechnology (2012)
Nature Reviews Drug Discovery (2010)
Nature Reviews Drug Discovery (2009)